Optimal designs for random effect models with correlated errors with applications in population phar

We consider the problem of constructing optimal designs for population pharmacokinetics which use random effect models. It is common practice in the design of experiments in such studies to assume uncorrelated errors for each subject. In the present paper a new approach is introduced to determine efficient designs for nonlinear least squares estimation which addresses the problem of correlation between observations corresponding to the same subject. We use asymptotic arguments to derive optimal design densities, and the designs for finite sample sizes are constructed from the quantiles of the corresponding optimal distribution function. It is demonstrated that compared to the optimal exact designs, whose determination is a hard numerical problem, these designs are very efficient. Alternatively, the designs derived from asymptotic theory could be used as starting designs for the numerical computation of exact optimal designs. Several examples of linear and nonlinear models are presented in order to illustrate the methodology. In particular, it is demonstrated that naively chosen equally spaced designs may lead to less accurate estimation.

[1]  Anthony C. Atkinson,et al.  Examples of the use of an equivalence theorem in constructing optimum experimental designs for random-effects nonlinear regression models , 2008 .

[2]  Holger Dette,et al.  Optimality criteria for regression models based on predicted variance , 1999 .

[3]  L Aarons,et al.  Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.

[4]  T. Schmelter.  Considerations on group-wise identical designs for linear mixed models , 2007 .

[5]  Andrej Pázman,et al.  Foundations of Optimum Experimental Design , 1986 .

[6]  Michael Jackson,et al.  Optimal Design of Experiments , 1994 .

[7]  H. L. Lucas,et al.  DESIGN OF EXPERIMENTS IN NON-LINEAR SITUATIONS , 1959 .

[8]  E. R. Garrett.  The Bateman function revisited: A critical reevaluation of the quantitative expressions to characterize concentrations in the one compartment body model as a function of time with first-order invasion and first-order elimination , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  G. Hohmann,et al.  On sequential and nonsequential D‐optimal experimental design , 1975 .

[10]  Peter J. Bickel,et al.  Robustness of Design against Autocorrelation in Time II: Optimally, Theoretical and Numerical Results for the First-Order Autoregressive Process , 1981 .

[11]  T. Schmelter.  The Optimality of Single-group Designs for Certain Mixed Models , 2007 .

[12]  Leon Shargel,et al.  Applied biopharmaceutics and pharmacokinetics , 1980 .

[13]  P. Bickel,et al.  Robustness of Design Against Autocorrelation in Time I: Asymptotic Theory, Optimality for Location and Linear Regression , 1979 .

[14]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[15]  Holger Dette,et al.  Designing Experiments with Respect to ‘Standardized’ Optimality Criteria , 1997 .

[16]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[17]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[18]  H. Chernoff.  Locally Optimal Designs for Estimating Parameters , 1953 .

[19]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[20]  Elvezio Ronchetti,et al.  Robustness of Design , 2005 .

[21]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[22]  J. Sacks,et al.  Designs for Regression Problems With Correlated Errors: Many Parameters , 1968 .

[23]  K. Chaloner,et al.  A geometric method for singular c-optimal designs , 2003 .

[24]  Holger Dette,et al.  Maximin optimal designs for the compartmental model , 2003 .

[25]  O. Krafft,et al.  Exact D‐Optimum Designs for Quadratic Regression , 1982 .

[26]  A. Telenti,et al.  Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[27]  K. Chaloner,et al.  Bayesian Experimental Design: A Review , 1995 .

[28]  J. Sacks,et al.  Designs for Regression Problems with Correlated Errors III , 1966 .

[29]  Drew Seils,et al.  Optimal design , 2007 .

[30]  Holger Dette,et al.  Optimal Designs for Dose-Finding Studies , 2008 .

[31]  Steven E. Rigdon,et al.  Model-Oriented Design of Experiments , 1997, Technometrics.

[32]  W. Näther.  Optimum experimental designs , 1994 .

[33]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[34]  K. Chaloner,et al.  Optimum experimental designs for properties of a compartmental model. , 1993, Biometrics.

[35]  I. Ford,et al.  The Use of a Canonical Form in the Construction of Locally Optimal Designs for Non‐Linear Problems , 1992 .

[36]  P. Thürmann,et al.  Interference of Uzara glycosides in assays of digitalis glycosides. , 2004, International journal of clinical pharmacology and therapeutics.

[37]  David A. Harville,et al.  Extension of the Gauss-Markov Theorem to Include the Estimation of Random Effects , 1976 .